logo

CARDIAC SC(NSDQ:CSCX)
Cardiac Science develops and markets life-saving external cardiac defibrillator devices and proprietary tachyarrhythmia detection software that monitors and automatically treats cardiac arrest victims. The company''s technology has multiple potential applications, including use in external defibrillators and bedside patient monitors widely used in hospitals throughout the world.
# Employees: 618
Address: 3303 Monte Villa Parkway,Bothell,WA,USA
Phone: 425 402-2000
Fax: 425 402-2001
Website: www.quinton.com
Email: investor@cardiacscience.com
Sector: Medical
Industry: MED PRODUCTS
Executive Officers
Ruediger Naumann-Etienn (Chmn.)
John R. Hinson (Presi.; C.E.O.; Dir.)
Michael K. Matysik (Sr. V.P.; C.F.O.)
Daphne Taylor (V.P.; Corp. Contr.)
Robert W. Berg (Chief Mktg. Off.,)
Dividend
Ex-Dividend Date: N/A
Annual Dividend: N/A
Current Dividend Yield: N/A
Dividend Paid (3 months): N/A
Indicated Dividend: N/A
Earnings
Last Earnings Date: 9/30/2009
Next Earnings Date(Expected): 3/11/2010
Mean EPS (Next Qtr): ($0.19)
Mean EPS (Year): ($0.49)
Mean Estimate(Long Term): $15.00
P/E Ratio(Based on EPS estimate): -0.010
Number of Estimates: 2
Shares Performance
Period CSCX Compare to S&P
YTD -72.13 % -76.94 %
4 Weeks -40.29 % -43.31 %
12 Weeks -32.36 % -37.02 %
Shares Information
Analyst Coverage: Y
Avg Volume: 127826
Shares Outstanding: 23M
Market Cap: $0.05B
52 Week High: $7.71
52 Week Low: $2.09
P/E Ratio: -0.010
PEG Ratio: -0.010
Split: On 9/1/2005 CSCX split by factor of 0.100
Earnings Performance
EPS Growth in Last Quarter: -100.00 %
EPS Growth in Last Year: -263.64 %
Sales Growth in Last Quarter: 7.67 %
Sales Growth in Last Quarter: -28.00 %
Financials
Qtr Book Value: $0.37
Cash Flow/Share: $0.39
Change in Payout Ratio: -0.010
Price/Sales: 0.290
Fundamental data is provided by Zacks Investment Research, market data is provided by AlphaTrade. , and Commentary and Press Releases provided by Quotemedia